Immunic, inc. reports second quarter 2021 financial results and highlights recent activity

New york, aug. 6, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the second quarter ended june 30, 2021 and highlighted recent activity. "so far this year, we have made outstanding progress with both our selective oral dhodh inhibitor, imu-838, as well as imu-935, a highly potent and selective inverse agonist of the transcription factor rorΓt, enabling what we believe will be an eventful and potentially transformative first half of 2022.
IMUX Ratings Summary
IMUX Quant Ranking